Rapid Micro Biosystems Raises $120 Million to Accelerate Global Expansion of Contaminant Testing Platform for Pharmaceutical and Vaccine Manufacturing
Rapid Micro Biosystems Raises $120 Million to Accelerate Global Expansion of Contaminant Testing Platform for Pharmaceutical and Vaccine Manufacturing
05/20/20, 10:03 AM
Location
lowellMoney raised
$120 million
Rapid Micro Biosystems, Inc., the leading provider of fully automated, high-throughput, rapid microbial detection technology for biopharmaceutical manufacturing, today announced the completion of a $120 million financing, including an equity investment led by Ally Bridge Group, along with Endeavour Vision and existing investors including Bain Capital Life Sciences, Longitude Capital, Xeraya Capital and Asahi Kasei Medical.
Company Info
Company
Rapid Micro Biosystems
Location
lowell, arkansas, united states
Additional Info
Rapid Micro Biosystems is the industry leader in automated detection of microbial contamination with innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products. The company’s Growth Direct™ platform - the first and only growth-based platform to fully automate traditional microbial testing - detects contamination more quickly, delivering compelling economic benefits to manufacturers while improving their quality control (QC) process. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Germany and the Netherlands. For more information visit www.rapidmicrobio.com.